Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $14.3 million.

  • Aytu Biopharma's Accounts Payables rose 2188.22% to $14.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.3 million, marking a year-over-year increase of 2188.22%. This contributed to the annual value of $10.6 million for FY2025, which is 278.26% up from last year.
  • As of Q4 2025, Aytu Biopharma's Accounts Payables stood at $14.3 million, which was up 2188.22% from $12.3 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Accounts Payables high stood at $19.3 million for Q2 2021, and its period low was $9.4 million during Q3 2021.
  • Its 5-year average for Accounts Payables is $12.8 million, with a median of $12.2 million in 2025.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 11801.8% in 2021, then crashed by 4293.95% in 2022.
  • Over the past 5 years, Aytu Biopharma's Accounts Payables (Quarter) stood at $15.6 million in 2021, then plummeted by 32.2% to $10.6 million in 2022, then fell by 1.01% to $10.5 million in 2023, then increased by 11.71% to $11.7 million in 2024, then rose by 21.88% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q4 2025, $12.3 million for Q3 2025, and $10.6 million during Q2 2025.